As per the terms of the agreement, BioFocus will use IMD’s natural screening product libraries and will further incorporate these as part of its own integrated drug discovery offerings.
IMD co-managing director Thomas Henkel said they believe that the combination of their natural product capabilities with the discovery capabilities of BioFocus will offer a powerful discovery solution at a time when there is already growing demand from the pharma, veterinary and agro industries to fill depleted pipelines.
BioFocus managing director Chris Newton said they believe that when InterMed’s natural product libraries and services are combined with their screening services, their engine for drug discovery will be substantially enhanced and more cost-effective for their clients.